Feed / TGTX

TG Therapeutics, Inc.

TGTX

Healthcare · 55.69 -0.6% today

Isolated · not yet confirmedMarket checked 26 Aug, 11:00 GMT-4

Jodie situation report

TG Therapeutics, Inc.'s current read is isolated; its market group is not confirming.

The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

What changed
  • Revenue increased 70.3% versus the comparable filing period.
  • Operating margin fell 15.7 percentage points.
Company-0.6% todayVolume comparison unavailable
Market group0 of 1 activeAnti-CD20 MS Therapies · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • R&D expense tripled in the three months, with management citing subcutaneous manufacturing work and higher clinical-trial costs.
  • April 2026 executive order seeks up to a 100% tariff on imported patented pharmaceutics, with exceptions for MFN pricing agreements or onshore manufacturing.

Invalidation: The isolated read changes if TGTX's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind TGTX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

OWLBlue Owl Capital Inc.lenderMay 6, 2026

Financial Update In March 2026, we entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital.

NVSNovartis AGcompetitorFeb 27, 2026

In addition, BRIUMVI competes with ofatumumab (Novartis AG), a patient/self-administered subcutaneous anti-CD20 monoclonal antibody approved for MS.

HTGCHercules Capital, Inc.lenderFeb 27, 2026

The $11.4 million increase is mainly due to $4.6 million of debt extinguishments costs incurred pertaining to the prior loan agreement with Hercules as well as increased interest expense pertaining to the Initial Term Loan with Blue Owl during the same period…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

TGTX is currently a Leader in the organic co-movement group Anti-CD20 MS Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for TGTX; it is not active in the latest market snapshot.